X

News

ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

ROCKVILLE, Maryland, March 24, 2017

ReveraGen BioPharma Inc, a privately held corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for vamorolone (VBP15) for the treatment of patients with Duchenne muscular dystrophy. This designation

More >

Actelion obtains an option vamorolone from ReveraGen

Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side effects associated with glucocorticoid therapy.
ALLSCHWIL, SWITZERLAND, and ROCKVILLE (MD), USA

More >

ReveraGen BioPharma Inc Initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy

Enrollment has begun in the Phase 2a clinical trial of vamorolone (VBP15) in the treatment of boys with Duchenne muscular dystrophy (DMD). The Phase 2a trial sponsored by ReveraGen BioPharma, is an open-label, multiple ascending dose study that will be

More >

ReveraGen BioPharma Receives $3M for Phase 2 Studies of Vamorolone in Duchenne

PPMD is thrilled to see the continued progress of VBP-15, now known as Vamorolone. Progress to date includes a first in-human study of healthy volunteers and animal data which suggests it has none of the side effects of steroids, does

More >

Parent Project Muscular Dystrophy and Foundation to Eradicate Duchenne Award $1 Million Grant to ReveraGen BioPharma

Parent Project Muscular Dystrophy (PPMD) and Foundation to Eradicate Duchenne (FED) today announced that they will award ReveraGen BioPharma (ReveraGen) a $1 million grant. The grant will help fund ReveraGen’s VBP15, a combined action drug that

More >

ReveraGen BioPharma Announces Start of Phase 1 Clinical Trial of VBP15 Dissociative Steroid Drug

ReveraGen BioPharma today announced the start of a Phase 1, first-in-human, clinical trial of a novel dissociative steroidal drug, VBP15, under development for Duchenne muscular dystrophy. Recruitment in the trial is underway, with the initial doses in the first volunteers

More >

January 2015: Action Duchenne announce £55,000 funding for biomarker panel research project

We are delighted to announce that the project titled ‘Definition of pharmacodynamics biomarker panel in a Phase 2a clinical trial of VBP15 in DMD’ has successfully completed our peer-review process. The aim of this proposal is to address the increasing

More >

July 2014: ReveraGen Drug Will Move to Human Testing

ReveraGen BioPharma, based in Silver Spring, Md., is moving ahead with a phase 1 trial of an experimental compound in development to treat Duchenne muscular dystrophy, made possible by a $2 million grant from U.S.-based MDA and three United Kingdom-based

More >

July 2014: International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

Four nonprofit organizations, the Muscular Dystrophy Association (USA), Joining Jack Foundation (UK), The Duchenne Research Fund (UK) and the Duchenne Children’s Trust (UK) have joined together to provide Phase 1 clinical trial funding for the first-in-human studies of VBP15, the

More >

September 2013: VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy

A preclinical study led by researchers at Children’s National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy (DMD). The results, published in EMBO Molecular Medicine, show that the drug,

More >